Forte Biosciences Inc (FBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$76.990.00%
Close 2026-08-28 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put FBRX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Advance clinical development of microbiome therapies: Clinical development stalled; company delisted and taken private via $77.00/share acquisition.
View ThesisManagement screens strong on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 56% in its worst 12-month stretch.
View RiskFBRX’s microbiome therapies depended on clinical progress, but development stalled. The company was delisted and taken private through a $77.00-per-share acquisition. The desk has no earnings history or earnings release for FBRX. It therefore provides no revenue trend or latest-quarter result to support the thesis. No valuation multiples or expectations read are available in the desk. Our model puts the next-quarter miss probability at 38%. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-08-28. FBRX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering FBRX (as of Aug 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare FBRX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FBRX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put FBRX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Targeting celiac disease aligns with potential product development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-28. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.